Drug
Grazoprevir clinical trials
Also written MK-5172 and MK-5172A.
- studies test it
- 28
- open now
- 0
- in phase 3
- 10
- first study started
- 2010
How studies write it
Studies that test it under each name
Name
Studies by the year they started
28 studies that test it; most in 2014 (8)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 8 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 11
- Phase 3
- 10
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 8
Merck Sharp & Dohme LLC (20) · University Hospital, Clermont-Ferrand (1) · Kyushu University (1) · Taoyuan General Hospital (1) · University of Zurich (1) · Taichung Veterans General Hospital (1) · Fundacion Clinic per a la Recerca Biomédica (1) · Norte Study Group (1)
Often tested with
Tested in the same studies.
Elbasvir (15) · Ribavirin (6) · Peginterferon alfa-2b (2) · Uprifosbuvir (2) · Ruzasvir (2) · MK-5172A (1) · Sofosbuvir (1) · MK-3682B (1)
Studies
Open first, then newest update. How each study uses grazoprevir is read from its arms, and is right about nine times in ten.
Testing it · 28
- Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe FibrosisCompletedPhase 3University Hospital, Clermont-FerrandNCT02973503Written as Elbasvir/Grazoprevir Fixed Dose Combination
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01353911Written as Grazoprevir
- Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)TerminatedPhase 2Merck Sharp & Dohme LLCNCT01440595Written as Grazoprevir
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)CompletedPhase 2Merck Sharp & Dohme LLCNCT03379506Written as Grazoprevir Oral Granules
- Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney TransplantationTerminatedPhase 4Taichung Veterans General HospitalNCT03723824Written as grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
- Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)CompletedPhase 2Merck Sharp & Dohme LLCNCT02133131Written as Grazoprevir/Elbasvir FDC
- An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)CompletedPhase 3Merck Sharp & Dohme LLCNCT02105662Written as Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
- A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)CompletedPhase 2Merck Sharp & Dohme LLCNCT01710501Written as Grazoprevir
- An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)CompletedPhase 3Merck Sharp & Dohme LLCNCT02105688Written as Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332720Written as Grazoprevir
- Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedPhase 2Merck Sharp & Dohme LLCNCT02332707Written as Grazoprevir
- The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)CompletedPhase 1Merck Sharp & Dohme LLCNCT01937975Written as Grazoprevir
- A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus ElbasvirCompletedPhase 4Kyushu UniversityNCT03144635Written as Grazoprevir plus Elbasvir
- Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected PatientsStatus unknownPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT02897596Written as Grazoprevir 100 mg/d 8 weeks
- Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infectionCompletedPhase 4Taoyuan General HospitalNCT03098121Written as grazoprevir and elbasvir
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)CompletedPhase 3Merck Sharp & Dohme LLCNCT02252016Written as Grazoprevir + Elbasvir
- Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)CompletedPhase 3Merck Sharp & Dohme LLCNCT02105467Written as Grazoprevir 100mg / Elbasvir 50 mg FDC
- Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02092350Written as Grazoprevir
- A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)CompletedPhase 2Merck Sharp & Dohme LLCNCT01716156Written as Grazoprevir
- Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)CompletedPhase 2Merck Sharp & Dohme LLCNCT02105454Written as Grazoprevir (GZR)
See all 28 studies that test grazoprevir →
Given in every arm · 6 — grazoprevir is usual care beside what is tested
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.WithdrawnPhase 3Fundacion Clinic per a la Recerca BiomédicaNCT02890719Written as Grazoprevir 100 mg/day
- A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)CompletedPhase 2Merck Sharp & Dohme LLCNCT01717326Written as Grazoprevir
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)CompletedPhase 3Merck Sharp & Dohme LLCNCT02105701Written as Grazoprevir + Elbasvir
- Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)CompletedPhase 2Merck Sharp & Dohme LLCNCT01932762Written as Grazoprevir
- Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedPhase 2Merck Sharp & Dohme LLCNCT02601573Written as Grazoprevir
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02115321Written as Grazoprevir
As the comparator · 1 — what is tested is compared with grazoprevir
Codes
What other systems call grazoprevir · ClinicalTrials.gg INT006221
- MeSH (NLM) C578009grazoprevirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4O2AB118LAGRAZOPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1734630One source FDA
- Wikidata Q83027548Grazoprevir monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166768GrazoprevirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C578009 | grazoprevir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4O2AB118LA | GRAZOPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1734630 | — | One source FDA |
| Wikidata | Q83027548 | Grazoprevir monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166768 | Grazoprevir | One source FDA |
Also registered as grazoprevir anhydrous (UNII 8YE81R1X1J · RxNorm 1871173).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.